Natural Killer Group 2 Member D ligand (NKG2DL)

Natural Killer Group 2 Member D ligands (NKG2DLs) are a family of stress-induced cell surface proteins, including MICA, MICB, and ULBP1-6, that are typically absent from healthy tissues but highly upregulated in response to cellular stress, viral infection, and malignant transformation. They serve as critical 'kill-me' signals that are recognized by the activating receptor NKG2D, which is constitutively expressed on natural killer (NK) cells and co-stimulatory on CD8+ T cells, thereby initiating the destruction of damaged or transformed cells. In the context of cancer, these ligands are expressed in over 80% of human malignancies, making them prime targets for immunotherapy; however, tumor cells often evade detection by shedding these ligands as soluble decoys that desensitize the immune system. Therapeutic strategies targeting NKG2DLs include monoclonal antibodies designed to block this shedding process and restore immune recognition, as well as chimeric antigen receptor (CAR) T and NK cell therapies that utilize the NKG2D receptor domain for tumor targeting. Furthermore, small molecule drugs like HDAC inhibitors and certain chemotherapies can be used to pharmacologically upregulate NKG2DL expression to sensitize tumors to immune attack. Clinical development is currently focused on leveraging these ligands in both hematologic and solid tumors, where high levels of soluble ligands often serve as poor prognostic biomarkers for existing immune checkpoint therapies.

Other names

MHC class I polypeptide-related sequence A (MICA)MHC class I polypeptide-related sequence B (MICB)UL16-binding proteins (ULBP1-6)Retinoic acid early transcript 1 (RAET1) familyStress-induced ligandsNKG2D-L

Drugs targeting NKG2D ligands utilize several mechanisms: monoclonal antibodies (e.g., CLN-619, DM919) bind to the alpha-3 domain of MICA/B to inhibit proteolytic shedding by ADAM and MMP proteases, thereby restoring surface ligand expression and promoting antibody-dependent cellular cytotoxicity (ADCC). NKG2D-based CAR-T and CAR-NK therapies (e.g., CYAD-01, NKX101) use the NKG2D extracellular domain to directly recognize and lyse ligand-expressing tumor cells. Additionally, certain chemotherapies and HDAC inhibitors upregulate ligand expression via the DNA damage response to enhance immune visibility.